has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Abbott India
to report net profit at Rs 77.5 crore, up 4.7 percent quarter-on-quarter.
Net Sales are expected to increase by 2 percent Q-o-Q (up 16.7 percent Y-o-Y) to Rs 752.5 crore, according to Centrum.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 2.4 percent Q-o-Q (up 25.2 percent Y-o-Y) to Rs 108 crore.Centrum's report on Abbott India
We expect the company to report superior performance, driven by its strong brands, new product launches and marketing thrust.
AIL has launched 17 new products in FY16 and these are likely to drive future growth.Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.